Tenpoint Therapeutics is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, Orasis Pharma, and LENZ Therapeutics, after getting FDA approval for its ...

Every budget gaming laptop worth its RGB stripes aims to deliver a satisfactory gaming experience while hiding its compromises. While the Acer Nitro V 16 AI (starts at $899, as tested) looks like a ...

LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today ...

Tenpoint Therapeutics Ltd, a global and commercial biotechnology company focused on developing groundbreaking treatments to improve vision in the aging eye, has announced that the US Food and Drug ...

The gradual loss of near vision that is a natural part of aging can be addressed by glasses, contact lenses, or even surgical procedures. A presbyopia eye drop developed by Tenpoint Therapeutics now ...

Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA approval (PDF) for Yuvezzi, a treatment for presbyopia, a common, age-related ...

U.S. FDA Approves YUVEZZI as the only dual-agent, once daily presbyopia-correcting eye drop Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking ...

Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 ...

Eye redness was not a commonly reported side effect in clinical trials of YUVEZZI. In BRIO I and BRIO II the reports of adverse events of ocular hyperemia (eye redness) were low. 1,2 In BRIO II, the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company, whose U.S ...

Yuvezzi is the first FDA-approved dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate. Phase III trials showed Yuvezzi significantly improved near visual acuity without ...